The Future of ER+/HER2- mBC Treatment
Dr Bardia provides his opinion on the current state of the ER+/HER2- treatment landscape and where elacestrant belongs in the current treatment paradigm.
Dr. Aditya Bardia: Based on the results of the EMERALD trial, Elacestrant potentially could be used in the second-line setting for patients with ER-positive HER2-negative metastatic breast cancer. EMERALD trial was as a single agent. There's also interest in combination therapy combining endocrine agents with other targeted agents such as PI3 kinase inhibitors as well as everolimus so that would be of interest as well.
Aromatase inhibitors are currently used in the adjuvant setting for patients with postmenopausal early breast cancer and they're also used in the metastatic setting as first-line therapy in combination with a CDK4/6 inhibitor. In terms of second, third-line setting, we sometimes do use aromatase inhibitors in combination with everolimus so if Elacestrant is FDA approved in the second, third-line setting, some physicians would consider using it as a single agent but there are others who would be interested in combination therapy in combination with a PI3 kinase mTOR or other targeted agents.
In terms of unmet need for patients with ER-positive, HER2-negative breast cancer, I can highlight three. The first is we need better endocrine agents. For example, fulvestrant is a selective estrogen receptor degrader but is given as an intramuscular shot, which can be inconvenient for patients so we need oral options for patients with ER-positive HER2-negative metastatic breast cancer. The second unmet need is once patients have endocrine-resistant disease, the mainstay of management right now is chemotherapy. Their interest in antibody-drug conjugates, trastuzumab deruxtecan, sacituzumab govitecan, but we need better agents that can help prolong survival for patients with ER-positive metastatic breast cancer and also improve quality of life in this setting. Then finally, the unmet need is to prevent metastatic ER-positive breast cancer. If we have good therapies in early breast cancer, if we can diagnose early breast cancer early, potentially we can prevent the emergence of metastatic disease, which would be wonderful for our patients.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
